DOR BioPharma, Inc.

DOR BioPharma, Inc. is a biopharmaceutical company dedicated to developing innovative products that address critical medical needs. DOR BioPharma, Inc. focuses on treatments for life-threatening side effects associated with cancer therapies, severe gastrointestinal disorders, and the creation of vaccines against specific bioterrorism agents.

DOR BioPharma, Inc.'s primary focus is orBec® (oral beclomethasone dipropionate or BDP), a powerful corticosteroid designed for localized action. This product is currently in development for treating acute gastrointestinal Graft-versus-Host disease (GI GVHD), a frequent and potentially fatal complication arising from allogeneic hematopoietic cell transplantation. DOR BioPharma, Inc. is committed to improving patient outcomes through advanced research and pharmaceutical development.

DOR BioPharma, Inc. is dedicated to advancing healthcare through its research and development efforts. The company is actively working to expand its portfolio and bring novel therapies to market. DOR BioPharma, Inc. is poised for continued growth and innovation in the biopharmaceutical sector. We invite the manager of DOR BioPharma, Inc. to create a customized and exclusive company showcase and product listing on our platform.